KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Net Income (2016 - 2025)

Emergent BioSolutions (EBS) has 14 years of Net Income data on record, last reported at -$54.6 million in Q4 2025.

  • For Q4 2025, Net Income fell 74.44% year-over-year to -$54.6 million; the TTM value through Dec 2025 reached $52.6 million, up 127.6%, while the annual FY2025 figure was $52.6 million, 127.6% up from the prior year.
  • Net Income reached -$54.6 million in Q4 2025 per EBS's latest filing, down from $51.2 million in the prior quarter.
  • Across five years, Net Income topped out at $177.9 million in Q4 2021 and bottomed at -$283.1 million in Q2 2024.
  • Average Net Income over 5 years is -$45.1 million, with a median of -$32.0 million recorded in 2021.
  • Peak YoY movement for Net Income: surged 657.6% in 2021, then tumbled 4932.43% in 2023.
  • A 5-year view of Net Income shows it stood at $177.9 million in 2021, then crashed by 142.61% to -$75.8 million in 2022, then soared by 34.7% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then plummeted by 74.44% to -$54.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$54.6 million in Q4 2025, $51.2 million in Q3 2025, and -$12.0 million in Q2 2025.